JUNEL 24 Fe Rx
Generic Name and Formulations:
Norethindrone acetate 1mg, ethinyl estradiol 20mcg (24 light yellow tabs); inert+ (4 tabs); +contains ferrous fumarate 75mg.
Indications for JUNEL 24 Fe:
1 tab daily for 28 days; repeat.
Premenarchal: not recommended.
Thrombophlebitis or thromboembolic disease. History of DVT, cerebrovascular or coronary artery disease. Thrombogenic valvular disease. Severe hypertension. Diabetes with vascular disease. Headaches with focal neurologic symptoms. Major surgery with prolonged immobilization. Known or suspected breast carcinoma, endometrial or other estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Pregnancy-related cholestasis. Hepatic disease or tumors. Pregnancy (Cat.X).
Cigarette smoking increases risk of serious cardiovascular events.
Increased risk of cardiovascular events esp. in cigarette smokers >35yrs of age; not recommended. Discontinue if thrombotic event, unexplained visual changes, jaundice, or headache/migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism, and during and after prolonged immobilization. Cardio- or cerebrovascular diseases. Gallbladder disease. Obesity. Diabetes. Prediabetes. Hypertriglyceridemia. Depression. Conditions aggravated by fluid retention; monitor. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea, retinal vein thrombosis. Monitor BP. Do regular complete physical exams. Nursing mothers: not recommended.
Progestin + estrogen.
May be antagonized by anti-infectives and anticonvulsants (eg, phenytoin, phenylbutazone, barbiturates, carbamazepine, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate), St. John’s wort; use backup contraception. May be potentiated by atorvastatin, acetaminophen, ascorbic acid, or CYP3A4 inhibitors (eg, itraconazole, ketoconazole). May be affected by HIV protease inhibitors. May antagonize acetaminophen, temazepam, salicylic acid, morphine, clofibric acid. May potentiate cyclosporine, prednisolone, theophylline. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins, serum folate).
Headache, vaginal candidiasis, upper respiratory tract infection, nausea, menstrual cramps, breast tenderness, sinusitis, bacterial vaginitis, abnormal cervical smear, acne, UTI, mood swings, weight gain, vomiting, metrorrhagia; serious cardiovascular events and stroke, vascular events, hypertension, irregular uterine bleeding, liver disease.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Trends in Bisphosphonate Use and Hip Fracture Rates in Denmark
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners